One example would be with lambda-cyhalothrin. That is one important crop protection product on which it seems the PMRA knows it made a mistake with regard to how that reassessment was done.
I think we heard this from our previous witness, but I want to ask you as well. With this increase in fees and this additional funding, we would be 10 times more expensive than our closest competitor and trading partner, the United States, making us that much more uncompetitive. Are you seeing any better service for this increase in fees or these additional government dollars that have been given to the PMRA?